Previous 10 | Next 10 |
home / stock / bct:cc / bct:cc news
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy...
Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platform Bria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells and natural killer cells Initiation of GMP manufacturing ...
A look at the top 10 most actives in Canada Horizons Cdn Select Universe Bond ETF (HBB) rose 0.7% to $46.87 on volume of 15,668,391 shares FLINT Corp. (FLNT) rose 50.0% to $0.045 on volume of 15,219,473 shares NICAN Limited (NICN) fell 11.5% to $0.115 on volume of 11,487,306 shares ATEX...
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular pain Heavily pre-treated patient had failed 7 prior regimens including ant...
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint inhibitor (CPI) Tumor reductions observed in heavily pretreated patient...
In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of similar studies* Progression Free Survival (PFS) was similar or better than last regimen in 40% of the patients highlighting clinica...
VersaBank (VBNK:CA) is expected to report $0.44 for Q4 2023 Genesis Land Development Corp. (GDC:CA) is expected to report for Q2 2024 Aberdeen International Inc. (AAB:CA) is expected to report for Q1 2024 Crown Capital Partners Inc. (CRWN:CA) is expected to report for Q1 2024 Diam...
Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*). 32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit. ...
BriaCell’s Bria-IMT ™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning “Cold” tumors “Hot” on ImmunoPET imaging Advanced protein array technologies showed unique ant...
After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction recorded. Heavily treated patient had 7 prior failed regimens ....
News, Short Squeeze, Breakout and More Instantly...
Briacell Therapeutics Corp. Company Name:
BCT:CC Stock Symbol:
TSXC Market:
Briacell Therapeutics Corp. Website:
A look at the top 10 most actives in Canada TC Energy Corporation (TRP) rose 0.2% to $53.5 on volume of 22,020,828 shares Fission Uranium Corp. (FCU) rose 0.0% to $1.19 on volume of 19,601,007 shares Victoria Gold Corp. (VGCX) fell 81.7% to $1.36 on volume of 15,148,780 shares Whitecap ...
A look at the top 10 most actives in Canada Fission Uranium Corp. (FCU) rose 17.8% to $1.19 on volume of 38,584,199 shares TC Energy Corporation (TRP) rose 1.3% to $53.39 on volume of 20,277,299 shares iShares S&P/TSX 60 Index ETF (XIU) rose 1.4% to $33.0001 on volume of 14,881,992 sh...
A look at the top 10 most actives in Canada Cenovus Energy Inc. (CVE) fell 0.9% to $25.51 on volume of 57,122,592 shares TC Energy Corporation (TRP) rose 0.9% to $52.71 on volume of 31,605,194 shares PrairieSky Royalty Ltd. (PSK) fell 4.7% to $25.89 on volume of 26,954,600 shares Canadi...